Safety and Efficacy of PC945 in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis

Overview

Información sobre este estudio

The purpose of this study is to assess the effectiveness of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory Invasive Pulmonary Aspergillosis (IPA).

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Participant has proven or probable IPA according to the 2019 European Organization for Research and Treatment of Cancer/ Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) consensus definitions or according to the 2010 International Society for Heart and Lung Transplantation (ISHLT) consensus statements for the definitions of infections in cardiothoracic transplant recipients.
  • Participant's IPA has an unfavorable response to adequate antifungal therapy.

Exclusion Criteria:

  • Participant with a known or suspected concomitant medical condition or post-surgery complication that, in the opinion of the Investigator, may jeopardize adherence to the protocol requirements or impede the accurate measurement of efficacy or may be an unacceptable additional risk to the Participant should he/she participate in the study.
  • Participant who has previously received PC945.
  • Participant with a known history of allergy, hypersensitivity, or any previous serious reaction to any component of the PC945 or placebo formulations.
  • Participant who is participating, or who is due to participate at any time during the study, in a therapeutic or diagnostic clinical trial.

Eligibility last updated 7/29/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Lisa Brumble, M.D.

Abierto para la inscripción

Contact information:

Kevin Kurtz M.S.

Kurtz.Kevin@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20543271

Mayo Clinic Footer